12/16
08:05 am
ebs
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
12/12
08:30 am
ebs
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Medium
Report
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
12/2
03:41 pm
ebs
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/30
03:33 am
ebs
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
Medium
Report
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
11/26
02:06 pm
ebs
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
08:00 am
ebs
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
Low
Report
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
11/12
04:27 pm
ebs
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors [Yahoo! Finance]
Low
Report
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors [Yahoo! Finance]
11/12
04:01 pm
ebs
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Medium
Report
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
11/11
02:00 pm
ebs
PDA Releases Three New Foundational Documents to Advance Aseptic Processing and Sterilizing Filtration Practices
Low
Report
PDA Releases Three New Foundational Documents to Advance Aseptic Processing and Sterilizing Filtration Practices
11/9
01:13 am
ebs
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
Medium
Report
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
11/1
01:04 am
ebs
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
High
Report
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
10/29
04:15 pm
ebs
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
High
Report
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
10/28
08:00 am
ebs
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Medium
Report
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
10/28
06:18 am
ebs
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Zacks Research to a "hold" rating.
10/24
12:21 pm
ebs
Emergent Biosolutions (NYSE:EBS) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Emergent Biosolutions (NYSE:EBS) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
07:45 am
ebs
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
Low
Report
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
10/1
05:02 am
ebs
Prefilled Syringe Fill Finish Manufacturing Research Report 2025-2035: 100+ Providers Identified as Catalent, AMRI, Sandoz and Pierre Fabre Lead Clinical and Commercial Operations [Yahoo! Finance]
Low
Report
Prefilled Syringe Fill Finish Manufacturing Research Report 2025-2035: 100+ Providers Identified as Catalent, AMRI, Sandoz and Pierre Fabre Lead Clinical and Commercial Operations [Yahoo! Finance]